Tyvalzi 30 mcg Combipack Injection 1's

Tyvalzi 30 mcg Combipack Injection 1's belongs to the class of endothelin B receptor agonists used in the treatment of cerebral ischemic stroke. Cerebral ischemic stroke is a condition in which the lack of blood supply to the brain stops brain tissue from obtaining oxygen and nutrients, resulting in potential brain damage, neurological impairments, or death.

Tyvalzi 30 mcg Combipack Injection 1's contains sovateltide, a neural progenitor cell therapeutic agent. It works by stimulating neural progenitor cells to create neurovascular remodelling. This produces new neurons and blood vessels, thus increasing cerebral blood flow and anti-cell death activity.

Tyvalzi 30 mcg Combipack Injection 1's will be administered by a trained healthcare professional. Do not self administer. This medicine may cause side effects like abdominal discomfort, vomiting, sweating and uneasiness. These side effects generally occur when administered in higher doses. However, inform your doctor immediately if you observe any such side effects.

Tyvalzi 30 mcg Combipack Injection 1's should be avoided if you are allergic to it. Before receiving the medicine, inform your doctor if you have any medical conditions like acute or chronic subdural hematoma, subarachnoid hemorrhage, epidural hemorrhage, intracranial hemorrhage, intracerebral hematoma, or intraventricular hemorrhage, and liver/kidney disease. Also, let your doctor know if you are pregnant or breastfeeding before starting the treatment. 

Tyvalzi 30 mcg Combipack Injection 1's is used in the treatment of treatment of ischemic stroke and pulmonary arterial hypertension (PAH). The detailed uses of Tyvalzi 30 mcg Combipack Injection 1's are as follows:

• Treatment of cerebral ischemic stroke:Tyvalzi 30 mcg Combipack Injection 1's treats cerebral ischemic stroke by enhancing neuro regeneration and improving blood flow to the affected area of the brain.
• Pulmonary arterial hypertension (PAH):Tyvalzi 30 mcg Combipack Injection 1's can potentially alleviate Pulmonary Arterial Hypertension (PAH) by relaxing and widening pulmonary arteries, reducing blood pressure.
• Neuroprotection:Tyvalzi 30 mcg Combipack Injection 1's shields brain cells from damage and enhances mitochondrial function for better energy production.

• Follow your doctor's instructions on the dosage and timing of this medication.
• Tyvalzi 30 mcg Combipack Injection 1's is administered by the doctor or nurse in a healthcare setting.
• Do not self-administer.

Tyvalzi 30 mcg Combipack Injection 1's is used in the treatment of cerebral ischemic stroke. It contains sovateltide, a neural progenitor cell therapeutic agent. It works by stimulating neural progenitor cells to create neurovascular remodelling. This produces new neurons and blood vessels, thus increasing cerebral blood flow and anti-cell death activity. Tyvalzi 30 mcg Combipack Injection 1's has antioxidant, anti-inflammatory, and anti-cell death properties, which may help stroke victims regain their neurological and motor function by reducing brain cell death.

Before taking the Tyvalzi 30 mcg Combipack Injection 1's, let your doctor know you're allergic to any ingredient. Inform your doctor about your medical history and other medications you are currently taking to rule out any potential negative effects. Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding or if you have any other medical conditions, including active internal bleeding, current severe uncontrolled hypertension, acute or chronic subdural hematoma, subarachnoid hemorrhage, epidural hemorrhage, intracranial hemorrhage, intracerebral hematoma, or intraventricular hemorrhage, and liver/kidney disease. Tyvalzi 30 mcg Combipack Injection 1's is not recommended for use in children below 12 years of age as the safety and efficacy are not established.